Mural Oncology to Receive $2.035 Cash Per Share from XOMA Royalty Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Source: Globenewswire
- Transaction Price Determination: According to the transaction agreement dated August 20, 2025, Mural Oncology's additional price per share has been finalized at $0.000, resulting in shareholders receiving $2.035 in cash per share upon acquisition closure, which will enhance short-term returns for investors.
- Acquisition Agreement Details: The acquisition is being conducted by XOMA Royalty's wholly-owned subsidiary, XRA 5 Corp., and is expected to close in early December 2025, subject to the satisfaction of outstanding closing conditions and the sanction of the scheme by the Irish High Court, ensuring the transaction's legality and smooth execution.
- Legal Compliance: The acquisition follows the scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act, ensuring compliance with local legal requirements, which reduces potential legal risks and boosts investor confidence in the transaction.
- Forward-Looking Statements: The announcement includes forward-looking statements regarding Mural, XOMA Royalty, and Sub's intentions to complete the acquisition, highlighting a positive outlook for future growth despite existing uncertainties, indicating the companies' commitment to strategic expansion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
